Ancora Advisors’s Royalty Pharma RPRX Stock Holding History

Ancora Advisors’s Portfolio RPRX Stock Details RPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q3	–	Sell	-28	Closed	-$738	–	1878
2024 Q2	$738	Buy	+28	New	+$776	﹤0.01%	1679

Other funds holding RPRX

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Ancora Advisors's RPRX Position: Q3 2024 in Review

Ancora Advisors sold out of Royalty Pharma (RPRX) in Q3 2024, closing a stake of 28 shares — an estimated $738 sold.

Ancora Advisors first reported a position in RPRX in Q2 2024 and held it in 1 quarter. The position peaked at $738 in Q2 2024. 395 funds tracked by Wall St. Rank hold RPRX as of Q3 2024.

Ancora Advisors reported no remaining Royalty Pharma position as of Q3 2024 after selling out during the quarter.
Ancora Advisors sold 28 Royalty Pharma shares in Q3 2024, an estimated $738.
Ancora Advisors first reported a position in Royalty Pharma in Q2 2024 and held it in 1 quarter.
Ancora Advisors's Royalty Pharma position peaked at $738 in Q2 2024.
395 funds tracked by Wall St. Rank held Royalty Pharma as of Q3 2024.

Based on Ancora Advisors's 13F filing for Q3 2024, filed 14 Nov 2024.